|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||165.92 - 168.30|
|52 Week Range||129.82 - 170.00|
|PE Ratio (TTM)||62.50|
|Earnings Date||Apr 26, 2018|
|Forward Dividend & Yield||1.88 (1.13%)|
|1y Target Est||174.96|
ConMed (CNMD) expects to witness the positive impact of around 0.5–1.0 percentage points on its fiscal 2018 adjusted gross margin, attributable to various cost-saving initiatives. ConMed has also projected an improvement of ~0.2–0.5 percentage points in its ratio of SG&A (selling, general, and administrative) expenses to total sales for fiscal 2018 on a YoY (year-over-year) basis. ConMed also expects its 2018 R&D (research and development)-to-sales ratio to be at the higher end of the projected range of 4.5%–5%.
ConMed (CNMD) expects to report revenue growth in the range of 5%–6.5% on a reported basis and in the range of 4.0%–5.0% on a CC (constant currency) basis for fiscal 2018. The company has projected a favorable top-line impact of 100–150 basis points, resulting from foreign exchange movements for fiscal 2018. In 2017, ConMed reported a ~4.3% YoY (year-over-year) rise in revenues on a CC basis, which would be in line with the average revenue growth in the medical technology industry.
Headquartered in Utica, New York, ConMed (CNMD) currently employs 3,100 people worldwide. In 4Q17, ConMed reported total sales close to $222.6 million, which represents a YoY (year-over-year) rise of ~7.9% on a CC (constant currency) basis and 9% on a reported basis, driven by the robust uptake of its products in the US and in international geographies. For fiscal 2017, ConMed reported total sales close to $796 million, which represents a YoY rise of ~4.3%, both on a CC and reported basis.
On February 26, 2018, Stryker (SYK) closed trading at $165.77. According to Stryker, it has delivered sales growth consistently higher than that of the average performance of the medical technology industry over the past several years. The stock is currently trading above its 200-day moving average of $160.03 and its 50-day moving average of $160.03.
NEW YORK, March 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
In 4Q17, the momentum in Stryker’s (SYK) Mako robot installations continued with total worldwide installations of 35 Mako robots, of which 27 were in the United States. The trend emphasizes Mako’s expansion in new and underpenetrated markets. Since Mako’s launch, Stryker has been focused on training an increasing number of surgeons on its total knee application, which should help increase its utilization rate.
On February 15, 2018, Stryker (SYK) announced that the FDA had provided an expanded indication for its Trevo Clot Retriever. Trevo can now be used as a frontline treatment for acute ischemic stroke patients from the onset of the stroke symptoms for up to 24 hours. The expanded indication will allow Stryker to tap the additional population of patients who had been unable to get the Trevo treatment due to the higher duration of ischemic stroke condition persistence.
Stryker (SYK) is a medical technology company that offers products and services in the areas of orthopedics, medical and surgical, neurotechnology, and spine. Of the 28 analysts covering Stryker in February 2018, 11 of them have given the stock a “strong buy” rating, and eight have given it a “buy.” Seven of them have given it a “hold,” and two have given it a “sell” or lower rating. Of the 25 analysts covering Boston Scientific (BSX) in February 2018, 13 of them have given the stock a “strong buy,” seven have given it a “buy,” and five have given it a “hold.” The mean rating for the stock is 1.7 with a target price of $31.50.
Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific
Headquartered in Frisco, Texas, Integer Holdings Corporation (ITGR) is a medical device outsource (or MDO) manufacturing company. In addition, Integer Holdings Corporation develops batteries for use in the energy and military space. Of the four analysts covering Integer Holdings Corporation in February 2018, two analysts gave the stock a “buy” or a higher rating while two analysts gave it a “hold” rating.